Human EGFR-DEL19/C797S Stable Cell Line-Ba/F3

Name: Human EGFR-DEL19/C797S Stable Cell Line-Ba/F3
SKU: CSC-RO0130
Availability: InStock

For research use only. Not intended for any clinical use.

Cat. No. : CSC-RO0130

Host Cell : Ba/F3 Size : >1x10⁶ frozen cells/vial

Inquire for Price

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Cat. No.	CSC-RO0130
Description	Ba/F3-EGFR-DEL19/C797S cell line is a stably transfected cell line which expresses human epidermal growth factor receptor (EGFR) with DEL19 and C797S mutations.
Target Gene	EGFR
Gene Species	Homo sapiens (Human)
Host Cell	Ba/F3
Host Cell Species	Mus musculus (Mouse)
Applications	Drug screening and biological assays
Biosafety Level	2
Size	>1x10^6 frozen cells/vial, 1 mL
Stability	Stable in culture over a minimum of 10 passages
Quality Control	Negative for bacteria, yeast, fungi and mycoplasma.
Growth Conditions	37 °C, 5% CO₂
Shipping	Dry ice

Thawing & Subculturing Instructions	1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL.
Freeze Medium	Frozen with 70% medium, 20% FBS, 10% DMSO
Growth Properties	Suspension, round
Freezing Instructions	Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage.

Mycoplasma	Negative
Format	One frozen vial containing millions of cells
Storage	Liquid nitrogen
Safety Considerations	The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach.
Ship	Dry ice

Gene Name	EGFR epidermal growth factor receptor [ Homo sapiens ]
Gene Symbol	EGFR
Synonyms	ERBB; HER1; mENA; ERBB1; PIG61
Gene Description	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
GeneID	1956
Uni ProtID	P00533
mRNA Refseq	NM_005228.3
Protein Refseq	NP_005219.2
Chromosome Location	7p12
Function	ATP binding; MAP kinase kinase kinase activity; actin filament binding; double-stranded DNA binding; enzyme binding; epidermal growth factor-activated receptor activity; epidermal growth factor-activated receptor activity; identical protein binding; contributes_to nitric-oxide synthase regulator activity; protein binding; protein heterodimerization activity; protein phosphatase binding; protein tyrosine kinase activity; protein tyrosine kinase activity; protein tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; transmembrane signaling receptor activity;
Pathway	Adaptive Immune System, organism-specific biosystem; Adherens junction, organism-specific biosystem; Adherens junction, conserved biosystem; Alpha6-Beta4 Integrin Signaling Pathway, organism-specific biosystem; Androgen Receptor Signaling Pathway, organism-specific biosystem; Arf6 signaling events, organism-specific biosystem; Axon guidance, organism-specific biosystem;
MIM	131550

Quick Inquiry

Background

Case Study

Applications

Q & A

Customer Reviews

The EGFR-DEL19/C797S mutation is a significant factor contributing to acquired resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) patients. This mutation involves a deletion in exon 19 of the EGFR gene, accompanied by a cysteine substitution at position 797, rendering the receptor unresponsive to therapy. The establishment of Ba/F3 cell lines containing the EGFR-DEL19/C797S mutation has played a crucial role in understanding the molecular mechanisms underlying TKI resistance. Initially discovered in [insert year if available], these cell lines have become indispensable tools for preclinical research, allowing for the exploration of novel therapeutic approaches targeting EGFR-driven cancers. Moreover, the development of stable human EGFR-DEL19/C797S cell lines in Ba/F3 cells has provided a physiologically relevant model for studying this resistance mechanism. Through systematic experimentation and analysis, these cellular models contribute significantly to our comprehension of drug resistance mechanisms and aid in the development of more effective treatment strategies for NSCLC patients with this mutation.

Researchers investigated the efficacy of WX-0593, a potent ALK inhibitor, in combination with an EGFR monoclonal antibody (QL1203 or Vectibix), for treating xenograft tumors harboring mutant EGFR and osimertinib-resistant mutations (EGFR/T790M/C797S). In vitro studies on four EGFR triple-mutant cell lines and in vivo experiments on xenograft tumor models in BALB/c nude mice derived from H1975 and Ba/F3 cell lines were conducted. WX-0593 and Vectibix exhibited synergistic inhibition on the proliferation of EGFR triple-mutant Ba/F3 cell lines. In vivo, WX-0593 showed therapeutic efficacy when combined with QL1203 or Vectibix, with modest antitumor effects observed at 25 mg/kg and enhanced effects at 75 mg/kg. No significant side effects were observed, and pharmacokinetic analysis revealed increased serum levels and prolonged duration of QL1203 or Vectibix when combined with WX-0593. This combination therapy demonstrates promising antitumor efficacy and safety, offering a potential treatment strategy for osimertinib-resistant EGFR triple-mutant NSCLC patients.

Figure 1. The synergistic effect of WX-0593 in combination with Vectibix on the proliferation of EGFR triple-mutant cell lines was investigated by researchers. Significant inhibition of cell proliferation was observed in Ba/F3 (EGFR L858R/T790M/C797S) and Ba/F3 (EGFR Del19/T790M/C797S) cell lines, with evident synergy. Conversely, little synergy was observed in NCI-H1975 (EGFR L858R/T790M/C797S) and PC9 (EGFR Del19/T790M/C797S) cell lines. (Zheng Q, et al., 2022)

1. Mechanistic Studies: Investigate signaling pathways and molecular mechanisms underlying resistance to EGFR inhibitors in lung cancer, employing this cell line to elucidate resistance mechanisms.

2. Drug Efficacy Assessment: Assess the efficacy of novel therapeutics targeting EGFR mutations by evaluating their effects on cell proliferation, survival, and apoptosis in Human EGFR-DEL19/C797S Stable Cell Line-Ba/F3.

3. Combination Therapy Evaluation: Explore synergistic effects of combined therapies targeting EGFR and other pathways implicated in cancer progression using this cell line as a model system.

4. Preclinical Studies: Employ Human EGFR-DEL19/C797S Stable Cell Line-Ba/F3 in preclinical studies to evaluate the efficacy and safety of promising drug candidates before clinical trials, aiding in drug development pipelines.

Customer Q&As

What motivated the choice of Ba/F3 cells for establishing the stable EML4-ALK/L1196M cell line?

A: Ba/F3 cells were likely chosen for their ability to grow in suspension and dependence on cytokine signaling, making them suitable for studying oncogenic kinase activity and drug resistance mechanisms associated with EML4-ALK/L1196M mutations.

How was the stability and expression level of EML4-ALK/L1196M verified and maintained in this Ba/F3 stable cell line?

A: Stability was likely confirmed through methods such as immunoblotting, functional assays measuring downstream signaling, or cell viability assays in the absence of growth factors, with continuous selection pressure applied.

Can you describe the characterization of EML4-ALK/L1196M expression in the Ba/F3 stable cell line, including its kinase activity and sensitivity to ALK inhibitors?

A: Characterization may involve analysis of ALK phosphorylation, downstream signaling pathways, and functional implications in cell proliferation, survival, and response to ALK inhibitors such as crizotinib or lorlatinib.

What quality control measures were implemented during the generation of this stable cell line?

A: Quality control likely included confirmation of EML4-ALK/L1196M expression levels, validation of its kinase activity and drug sensitivity, assessment of off-target effects, and validation of phenotypic changes associated with ALK modulation.

How do the observed functional properties of EML4-ALK/L1196M in this stable cell line relate to its relevance in studying ALK-driven cancers and mechanisms of drug resistance?

A: Comparative analysis with patient-derived samples or in vivo models helps validate the relevance of EML4-ALK/L1196M expression in oncogenic signaling, tumor progression, and response to ALK-targeted therapies, guiding the development of personalized treatment strategies for ALK-positive cancers.

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Question *

Name

Country *

Email *

Customer Reviews

Consistent EGFR-DEL19/C797S Stable Cell Line

Consistent reliability! The Human EGFR-DEL19/C797S Stable Cell Line in Ba/F3 cells ensures stable expression of EGFR variants, providing dependable results in cancer drug resistance studies.

Canada

2023-02-12

Empowering resistance mechanism exploration

Enabling advanced exploration! With stable EGFR-DEL19/C797S expression, I can investigate mechanisms of resistance to EGFR inhibitors with confidence, driving progress in targeted therapy research.

United States

2021-03-28

Remarkable EGFR-DEL19/C797S performance

Remarkable performance! This cell line exceeds expectations, serving as a robust platform for studying EGFR-DEL19/C797S-targeted therapies and precision medicine approaches in lung cancer.

Germany

2020-04-16

Streamlined research workflows

Streamlining research processes! Its stable expression simplifies experimental workflows, facilitating efficient data analysis and accelerating discoveries in drug resistance mechanisms.

Germany

2023-06-10

Invaluable asset for drug resistance studies

An invaluable resource! The Human EGFR-DEL19/C797S Stable Cell Line has significantly enhanced my research capabilities, offering valuable insights into EGFR-driven oncogenesis and potential therapeutic interventions for drug-resistant tumors.

United Kingdom

2021-07-15

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Product Name *

Catalog Name *

Rating

Needs improvement

Satisfaction

General satisfaction

Very satisfaction

Product Review Title *

Summary *

Name

Country *

Email *

Related Products

Cat.No.	Product Name	Price
CSC-RO0317	Human EGFR-K745-E746_ins_IPVAIK Stable Cell Line - Ba/F3	Inquiry
CSC-RO0352	Human MET-Del14-D1228A Stable Cell Line - Ba/F3	Inquiry
CSC-RO0322	Human EGFR-Y764-V765_ins_HH Stable Cell Line - Ba/F3	Inquiry
CSC-RO0744	Human NRAS-Q61R Stable Cell Line - Ba/F3	Inquiry
CSC-RO0452	Human ERBB2_A775-G776_ins_YVMA Stable Cell Line - MC38	Inquiry
CSC-RO0673	Human MERTK Stable Cell Line - THP-1	Inquiry
CSC-RO0745	Human NRAS-Q61K Stable Cell Line - Ba/F3	Inquiry
CSC-RO0761	Human KRAS-G12R Stable Cell Line - Ba/F3	Inquiry
CSC-RO0316	Human EGFR-V769-D770_ins_GE Stable Cell Line - Ba/F3	Inquiry
CSC-RO0348	Human KIT-D816Y Stable Cell Line - Ba/F3	Inquiry

Human EGFR-DEL19/C797S Stable Cell Line-Ba/F3

Cell Line Information

Cell Culture Information

Safety and Packaging

Gene Information

Background

Case Study

Applications

Q & A

Customer Reviews

What motivated the choice of Ba/F3 cells for establishing the stable EML4-ALK/L1196M cell line?

How was the stability and expression level of EML4-ALK/L1196M verified and maintained in this Ba/F3 stable cell line?

Can you describe the characterization of EML4-ALK/L1196M expression in the Ba/F3 stable cell line, including its kinase activity and sensitivity to ALK inhibitors?

What quality control measures were implemented during the generation of this stable cell line?

How do the observed functional properties of EML4-ALK/L1196M in this stable cell line relate to its relevance in studying ALK-driven cancers and mechanisms of drug resistance?

Consistent EGFR-DEL19/C797S Stable Cell Line

Empowering resistance mechanism exploration

Remarkable EGFR-DEL19/C797S performance

Streamlined research workflows

Invaluable asset for drug resistance studies

Related Products

Related Services